Global Drug-Resistant Tuberculosis Treatment Market, by Drug Classes (Amoxicillin/Clavulanate, Bedaquiline, Carbapenems with Clavulanic Acid, Clofazimine), By Disease Type (Multidrug-Resistant TB (MDR TB), Extensively Drug-resistant TB (XDR TB)), By Treatment Types (First-Line Anti-TB Drugs, Second-Line Anti-TB Drugs), By Distribution Channels (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Drug-Resistant Tuberculosis Treatment Market Overview:

The global drug-resistant tuberculosis treatment market is projected to reach a valuation of USD 1718.23 Mn by 2032 at a CAGR of 4.90%, from USD 1,064.94 Mn in 2022.

Since the advent of antibiotic-resistant tuberculosis, there has been a renewed interest in developing effective drugs to deal with this disease. Ideally, these new drugs will specifically target drug-resistant strains of Tuberculosis (TB) and will not affect patients with regular TB strains. The difficulty lies in finding compounds that are safe for human use, effective against bacteria, but do not interfere with other essential cellular functions. One of the most promising drug candidates is INB201. Tuberculosis is an infectious disease that is generally transmitted through the air by coughing or sneezing and has been increasingly difficult to cure in recent years due to the rise of antibiotic-resistant bacteria strains.

Despite this difficulty, new treatments developed in 2018 show promise in reversing this trend. Drug-resistant tuberculosis is a common, deadly, and difficult to treat illness. Tuberculosis is difficult to diagnose as well as treat because of its ability to change and adapt to new antibiotics, which leads to drug resistance. Drug-resistant TB can be treated with different combinations of antibiotics that are proven effective against the disease, but these treatments are expensive, hard for patients to take, and often cause side effects.

Tuberculosis is a disease that typically targets the lungs and can be transmitted through the air and infected fluids. The majority of individuals who contract tuberculosis belongs to developing countries, however, there is also a high rate of cases in developed countries as well. While it’s not possible to cure tuberculosis, there are many treatment options available. There has been an increase in drug-resistant tuberculosis cases in recent years, with around 10% of all newly diagnosed patients testing positive for drug resistance.

Global Drug-Resistant Tuberculosis Treatment Market Revenue (USD Mn), 2021–2031:

An increase in the number of patients with drug-resistant tuberculosis is predicted to boost the market for drug-resistant tuberculosis treatment. Overall, hospital usage of drug-resistant tuberculosis treatment, as well as increased awareness concerning them, are anticipated to contribute to the overall growth of this industry. The drug-resistant tuberculosis treatment market is being augmented by disease types such as Multidrug-Resistant Tuberculosis (MDR TB). Furthermore, increased demand from SMEs and numerous industrial verticals, as well as macroeconomic growth, are factors contributing to this market’s expansion. This market is steadily expanding on account of treatment types, such as first-line anti-TB drugs. Additionally, as common TB therapies don’t work on XDR TB, individuals with this severe form of TB must take an eight-drug cocktail for more than a year. Over this projected timeline, the increasing number of drug-resistant tuberculosis cases is also anticipated to act as a driving force for the global drug-resistant tuberculosis treatment market’s further growth.

Drug-resistant tuberculosis is a growing concern as the number of cases globally has continued to increase. The World Health Organization (WHO) estimates that in 2017, there were 450,000 individuals suffering from multidrug-resistant TB and at least 27,000 cases of totally drug-resistant TB. Drug-resistant TB treatment is more complicated and often requires a combination of antibiotics. Moreover, this treatment is costly, which in turn may hamper the economic growth of this market.

Drug-resistant tuberculosis treatment is a topic that is gradually garnering more and more attention. Over the past few years, the number of people who have died from this specific form of TB has risen dramatically. In response to this growing epidemic, many organizations have been working to develop new treatments for this disease. One such organization, Janssen Biotech, has been funded by grants from the National Institute of Health as well as the Bill & Melinda Gates Foundation to research new drugs. Factors such as this are expected to create lucrative opportunities for existing as well as emerging players in this market.

On July 15, 2021, UNIT4TB, a revolutionary, safe, and inexpensive treatment solution for Anti Tuberculosis science, was formally launched by 30 partners from 13 countries. The goal is to accelerate and improve clinical trials for drug-resistant and drug-sensitive TB by using existing and innovative pharmaceutical combinations, as well as highly successful TB treatment regimens. The emergence of Multidrug-Resistant Tuberculosis (MDR-TB) has sparked increased interest and financing for anti-TB drug research. Despite expanded efforts in the field, an integrated approach to TB medicine development remains lacking.

This research report on the global drug-resistant tuberculosis treatment market includes major company profiles such as

• Sanofi SA (France)
• Novartis AG (Switzerland)
• Endo International Plc (Ireland)
• CMP Pharma Inc. (United States)
• STI Pharma LLC (United States)
• Akorn Incorporated (United States)
• Lupin (India)
• Johnson & Johnson Services Inc. (United States)
• Macleods Pharmaceuticals Ltd. (India)
• Pfizer Inc. (United States)
• Hikma Pharmaceuticals PLC (United Kingdom)
• Others.

The Global Drug-Resistant Tuberculosis Treatment Market Segmentation is Based on Drug Classes, Disease Type, Treatment Types, Distribution Channels, and Region

Based on Drug Classes

• Amoxicillin/Clavulanate
• Bedaquiline
• Carbapenems with Clavulanic Acid
• Clofazimine
• Cycloserine
• Delamanid
• Ethambutol
• Ethionamide and Prothionamide
• Other Drug Classes

Based on Disease Type

• Multidrug-Resistant TB (MDR TB)
• Extensively Drug-Resistant TB (XDR TB)

Based on Treatment Types

• First-Line Anti-TB Drugs
• Second-Line Anti-TB Drugs
• Others Treatment Types

By Distribution Channels

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Other Distribution Channels

Based on Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

For the Drug-Resistant Tuberculosis Treatment Market research study, the following years have been considered to estimate the market size: